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Introduction
During the last decade, a considerable amount of new as potential risks and side-effects of iron therapy. We
hope that these new insights are of value for cliniciansinformation has accumulated for our understanding in
dealing with chronic renal failure patients.optimizing the therapy with recombinant human erythro-
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